Last reviewed · How we verify
Measles Mumps and Rubella Vaccine
The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses by exposing it to attenuated (weakened) forms of these pathogens.
The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses by exposing it to attenuated (weakened) forms of these pathogens. Used for Prevention of measles, Prevention of mumps, Prevention of rubella.
At a glance
| Generic name | Measles Mumps and Rubella Vaccine |
|---|---|
| Also known as | M-M-R II™ or Priorix™ |
| Sponsor | Sanofi |
| Drug class | Live attenuated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains live attenuated strains of measles, mumps, and rubella viruses that replicate in the body without causing disease in immunocompetent individuals. This triggers both humoral (antibody-mediated) and cell-mediated immune responses, generating protective immunity against natural infection with these three viral pathogens. Upon subsequent exposure to wild-type virus, the primed immune system rapidly produces neutralizing antibodies and cytotoxic T cells to prevent infection.
Approved indications
- Prevention of measles
- Prevention of mumps
- Prevention of rubella
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Rash
- Parotitis (mumps-like symptoms)
- Arthralgia/arthritis
Key clinical trials
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Measles Mumps and Rubella Vaccine CI brief — competitive landscape report
- Measles Mumps and Rubella Vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI